CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase 1 clinical trial to assess the safety and tolerability of MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor..

马萨诸塞州剑桥市——（商业新闻短讯）——MOMA Therapeutics是一家发现和开发新一代精确疗法的临床阶段生物制药公司，今天宣布，第一名患者已在其1期临床试验中服用，以评估MOMA-313的安全性和耐受性，MOMA-313是一种新型，高效和选择性的口服聚合酶theta解旋酶抑制剂。。

MOMA-313 is initially being developed in combination with a PARP inhibitor for patients with solid tumors harboring alterations in certain DNA repair genes, including subgroups of prostate cancer, pancreatic cancer and breast cancer.

MOMA-313最初是与PARP抑制剂联合开发的，用于患有某些DNA修复基因改变的实体瘤患者，包括前列腺癌，胰腺癌和乳腺癌亚组。

In parallel, MOMA announced the selection of a development candidate for its second lead program, MOMA-341, an oral potent and selective covalent Werner helicase inhibitor for treatment of cancers with microsatellite instability. An IND application filing with the FDA is anticipated in the first quarter of 2025..

与此同时，MOMA宣布为其第二个领先项目MOMA-341选择一个发展候选者，MOMA-341是一种口服强效和选择性共价Werner解旋酶抑制剂，用于治疗微卫星不稳定的癌症。预计将于2025年第一季度向FDA提交IND申请。。

“We are excited to be progressing two molecules with best-in-class potential toward the benefit of cancer patients in need in such close proximity,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. “The advance into clinical development for a company founded as an idea on paper a few years back is humbling.

MOMA首席执行官Asit Parikh医学博士说：“我们很高兴能够开发出两种具有同类最佳潜力的分子，以使如此接近的癌症患者受益。”。“几年前，一家以纸面想法成立的公司在临床开发方面取得的进展令人谦卑。

This progress serves as a testament to the excellence and unwavering commitment of the entire MOMA team.”.

这一进展证明了整个MOMA团队的卓越表现和坚定不移的承诺。”。

“Advancing two highly potent and selective drug candidates derived from our proprietary KNOMATIC platform toward the clinic is a unique privilege,” added Peter Hammerman, M.D., Ph.D., chief scientific officer of MOMA. “The goal with each candidate is to translate groundbreaking science into life-altering medicine.”.

。“每位候选人的目标是将开创性的科学转化为改变生命的医学。”。

About MOMA-313 and the Phase 1 Trial

关于MOMA-313和第一阶段试验

MOMA-313 is a potent and selective oral polymerase theta (Polθ) helicase inhibitor. Polθ is involved in the repair of DNA double-strand breaks that arise during DNA replication. The Phase 1 trial (NCT06545942) is a multi-center, open-label study designed to evaluate the safety and tolerability of MOMA-313 as monotherapy and in combination with the PARP inhibitor olaparib for patients where a PARP inhibitor would be expected to provide benefit.

MOMA-313是一种有效且选择性的口服聚合酶θ（Polθ）解旋酶抑制剂。Polθ参与DNA复制过程中产生的DNA双链断裂的修复。第一阶段试验（NCT06545942）是一项多中心，开放标签研究，旨在评估MOMA-313作为单一疗法的安全性和耐受性，并与PARP抑制剂奥拉帕尼联合用于PARP抑制剂有望提供益处的患者。

Response to PARP inhibitors can be short-lived due to primary and acquired resistance. Pre-clinical studies suggest that combining a PARP inhibitor with a Polθ inhibitor could afford unique mechanistic potential to deepen and prolong that response..

由于原发性和获得性耐药，对PARP抑制剂的反应可能是短暂的。临床前研究表明，将PARP抑制剂与Polθ抑制剂联合使用可以提供独特的机制潜力来加深和延长这种反应。。

About MOMA-341

关于MOMA-341

MOMA is developing MOMA-341 as an oral, potent and selective covalent inhibitor of Werner helicase with a novel chemical scaffold as monotherapy and in combination with chemotherapy and immunotherapy in tumors with microsatellite instability (e.g., colorectal, gastric, endometrial cancers).

MOMA正在开发MOMA-341作为Werner解旋酶的口服，有效和选择性共价抑制剂，具有新型化学支架作为单一疗法，并与化疗和免疫疗法联合用于微卫星不稳定的肿瘤（例如结直肠癌，胃癌，子宫内膜癌）。

About the KNOMATIC platform

关于KNOMATIC平台

The KNOMATIC platform integrates deep structural insights, advanced hit-finding technologies, and computation-enabled lead optimization to accelerate discovery of novel therapeutics targeting families of highly dynamic proteins, such as ATPases and GTPases. MOMA-313 and MOMA-341 were discovered and developed through the application of the KNOMATIC platform..

KNOMATIC平台集成了深入的结构见解，先进的命中发现技术和基于计算的铅优化，以加速发现针对高动态蛋白质家族（例如ATPases和GTPases）的新型疗法。通过KNOMATIC平台的应用，发现并开发了MOMA-313和MOMA-341。。

About MOMA Therapeutics

关于MOMA Therapeutics

MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation.

MOMA Therapeutics是一家临床阶段的下一代精准医学公司，致力于利用其专有的KNOMATIC平台，通过小分子方法靶向高度动态的蛋白质，这些蛋白质是人类疾病的基础。该平台旨在利用所有动态蛋白质固有的关键漏洞，即它们依赖于蛋白质构象的良好协调，逐步变化。

By focusing on genetically validated targets with high translation potential, MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies..

通过专注于具有高翻译潜力的基因验证目标，MOMA正在迅速推进其在临床上的反应管道。2024年1月，MOMA宣布与罗氏公司进行为期五年的发现合作，重点关注关键的癌症依赖性。。